CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 430 enrolled
Drug / intervention
GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02581410
NCT02581410Phase 3Completed
CompareCT.gov

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier

GlaxoSmithKline·interventional·Posted Oct 21, 2015·Updated Aug 28, 2018

In Brief

A Phase 3 clinical trial evaluating GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A) for Herpes Zoster. Completed, enrolled 430 participants across 32 sites.

Detailed Summary

The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' HZ/su vaccine in adults ≥ 65 years of age with and without Zostavax® vaccination at least 5 years earlier.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHerpes Zoster
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 21, 2015
Enrollment StartDec 15, 2015
Primary CompletionAug 30, 2016
Study CompletionAug 1, 2017
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 10.7 years ago

Interventions

GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)biological

2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm.